Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

Open access

Abstract

AIMS/HYPOTHESIS: The sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin slows progression of kidney function decline in type 2 diabetes. The aim of this study was to assess the effect of the SGLT2 inhibitor canagliflozin on biomarkers for progression of diabetic kidney disease (DKD). METHODS: A canagliflozin mechanism of action (MoA) network model was constructed based on an in vitro transcriptomics experiment in human proximal tubular cells and molecular features linked to SGLT2 inhibitors from scientific literature. This model was mapped onto an established DKD network model that describes molecular processes associated with DKD. Overlapping areas in both networks were subsequently used to select candidate biomarkers that change with canagliflozin therapy. These biomarkers were measured in 296 stored plasma samples from a previously reported 2 year clinical trial comparing canagliflozin with glimepiride. RESULTS: Forty-four proteins present in the canagliflozin MoA molecular model overlapped with proteins in the DKD network model. These proteins were considered candidates for monitoring impact of canagliflozin on DKD pathophysiology. For ten of these proteins, scientific evidence was available suggesting that they are involved in DKD progression. Of these, compared with glimepiride, canagliflozin 300 mg/day decreased plasma levels of TNF receptor 1 (TNFR1; 9.2%; p < 0.001), IL-6 (26.6%; p = 0.010), matrix metalloproteinase 7 (MMP7; 24.9%; p = 0.011) and fibronectin 1 (FN1; 14.9%; p = 0.055) during 2 years of follow-up. CONCLUSIONS/INTERPRETATION: The observed reduction in TNFR1, IL-6, MMP7 and FN1 suggests that canagliflozin contributes to reversing molecular processes related to inflammation, extracellular matrix turnover and fibrosis. Trial registration ClinicalTrials.gov NCT00968812.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-019-4859-4

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study analysis overview scheme. Molecular models were generated based on literature-derived data as well as in vitro-derived transcriptomics profiles for DKD and canagliflozin. Network interference analysis led to identification of pathophysiological DKD processes affected by canagliflozin treatment. Biomarkers in areas of network interference were selected and validated in samples from the completed CANTATA-SU clinical trial
Fig. 1 Study analysis overview scheme. Molecular models were generated based on literature-derived data as well as in vitro-derived transcriptomics profiles for DKD and canagliflozin. Network interference analysis led to identification of pathophysiological DKD processes affected by canagliflozin treatment. Biomarkers in areas of network interference were selected and validated in samples from the completed CANTATA-SU clinical trialCC BY · PubMed Central
Fig. 2 Canagliflozin MoA model construction. The literature-based MoA core model was constructed based on molecular features extracted from publications on SGLT2 inhibitors as well as from a manuscript on the impact of hyperglycaemia on tubulus cells [18]. The MoA core model (consisting of 74 connected protein-coding genes out of the set of 78) was expanded by deregulated transcripts from the in vitro cell culture experiment in HK2 cells, thus leading to the final canagliflozin MoA molecular model holding 105 protein-coding genes. Up- and downregulated protein-coding genes after canagliflozin treatment in HK2 cells are highlighted in red and green, respectively, in the final canagliflozin MoA molecular model. The intensity of colour indicates the level of up- and downregulation, with darker colours representing the greatest change. Cana, canagliflozin; CTRL, control; HG, high glucose; TX, transcriptomics. MGEA5 is also known as OGA
Fig. 2 Canagliflozin MoA model construction. The literature-based MoA core model was constructed based on molecular features extracted from publications on SGLT2 inhibitors as well as from a manuscript on the impact of hyperglycaemia on tubulus cells [18]. The MoA core model (consisting of 74 connected protein-coding genes out of the set of 78) was expanded by deregulated transcripts from the in vitro cell culture experiment in HK2 cells, thus leading to the final canagliflozin MoA molecular model holding 105 protein-coding genes. Up- and downregulated protein-coding genes after canagliflozin treatment in HK2 cells are highlighted in red and green, respectively, in the final canagliflozin MoA molecular model. The intensity of colour indicates the level of up- and downregulation, with darker colours representing the greatest change. Cana, canagliflozin; CTRL, control; HG, high glucose; TX, transcriptomics. MGEA5 is also known as OGACC BY · PubMed Central
Fig. 3 DKD–drug interference signature and selected biomarkers. The 44 protein-coding genes of the DKD–drug interference signature are shown along with genes encoding the three prognostic factors, MMP7, MMP8 and TNFR1, tightly connected to the interference signature. Protein-coding genes are grouped based on mechanistic involvement and molecular function. The ten biomarkers selected for measurements with Luminex technology in the CANTATA-SU study are highlighted in red. CTGF is also known as CCN2; TNFR1 is also known as TNFRSF1A
Fig. 3 DKD–drug interference signature and selected biomarkers. The 44 protein-coding genes of the DKD–drug interference signature are shown along with genes encoding the three prognostic factors, MMP7, MMP8 and TNFR1, tightly connected to the interference signature. Protein-coding genes are grouped based on mechanistic involvement and molecular function. The ten biomarkers selected for measurements with Luminex technology in the CANTATA-SU study are highlighted in red. CTGF is also known as CCN2; TNFR1 is also known as TNFRSF1ACC BY · PubMed Central
Fig. 4 Trial profile and patient disposition of the randomized controlled trial CANTATU-SU
Fig. 4 Trial profile and patient disposition of the randomized controlled trial CANTATU-SUCC BY · PubMed Central
Fig. 5 Change in biomarkers during glimepiride and canagliflozin treatment. Red squares/lines, glimepiride; light blue circles/lines, canagliflozin 100 mg/day; dark blue triangles/lines, canagliflozin 300 mg/day. Least square mean (LSM) changes are provided on each graph. Data are presented as mean ± 95% CI. n = 296 for all markers. *p ≤ 0.05, canagliflozin vs glimepiride
Fig. 5 Change in biomarkers during glimepiride and canagliflozin treatment. Red squares/lines, glimepiride; light blue circles/lines, canagliflozin 100 mg/day; dark blue triangles/lines, canagliflozin 300 mg/day. Least square mean (LSM) changes are provided on each graph. Data are presented as mean ± 95% CI. n = 296 for all markers. *p ≤ 0.05, canagliflozin vs glimepirideCC BY · PubMed Central
Fig. 6 Correlation (Pearson’s r) between changes in albuminuria and selected biomarkers during canagliflozin treatment. (a) Correlation between changes in biomarkers from baseline to week 52 in the overall population. (b) Correlation between changes in biomarkers from baseline to week 52 in the canagliflozin 300 mg treatment group. (c) Correlation between achieved biomarker levels at week 52 in the overall population. (d) Correlation between achieved biomarker levels at week 52 in the canagliflozin 300 mg treatment group. Red shading, statistically significant positive correlations; green shading, statistically significant negative correlations
Fig. 6 Correlation (Pearson’s r) between changes in albuminuria and selected biomarkers during canagliflozin treatment. (a) Correlation between changes in biomarkers from baseline to week 52 in the overall population. (b) Correlation between changes in biomarkers from baseline to week 52 in the canagliflozin 300 mg treatment group. (c) Correlation between achieved biomarker levels at week 52 in the overall population. (d) Correlation between achieved biomarker levels at week 52 in the canagliflozin 300 mg treatment group. Red shading, statistically significant positive correlations; green shading, statistically significant negative correlationsCC BY · PubMed Central
Fig. 7 Association between change in TNFR1 and change in eGFR during follow-up. (a) TNFR1 change stratified in tertiles (n = 98 in each tertile). (b) TNFR1 change stratified in subgroups: ≥30% TNFR1 reduction (n = 9); TNFR1 reduction between 30% and 0% (n = 128); >0% TNFR1 increase (n = 157)
Fig. 7 Association between change in TNFR1 and change in eGFR during follow-up. (a) TNFR1 change stratified in tertiles (n = 98 in each tertile). (b) TNFR1 change stratified in subgroups: ≥30% TNFR1 reduction (n = 9); TNFR1 reduction between 30% and 0% (n = 128); >0% TNFR1 increase (n = 157)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 458

Metadata

Authors
Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G.
Affiliations
  • University Medical Center Groningen (NL)
  • Innsbruck Medical University (AT)
  • Janssen Research & Development (United States) (US)
  • EmergenTec (Austria) (AT)
Corresponding author
Heerspink, Hiddo J. L.
Venue
Diabetologia
Published
2019-04-17
Volume
62
Issue
7
Pages
1154-1166
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2940024069
Cited by
457
References
34
Citations by year
2026: 37 · 2025: 62 · 2024: 61 · 2023: 79 · 2022: 89 · 2021: 79 · 2020: 33 · 2019: 12
FWCI
41.14
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Diabetologia (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
Funders
Janssen Research and Development
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
canagliflozin, SGLT2 inhibitors, diabetic nephropathy, inflammation, renal fibrosis, TNF receptor 1, interleukin-6, matrix metalloproteinase-7, FN1, extracellular matrix turnover, glimepiride, type 2 diabetes, plasma biomarkers, proximal tubular epithelial cells
MeSH terms
Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Cell Line, Diabetes Mellitus, Type 2, Fibronectins, Fibrosis, Humans, Inflammation, Kidney Diseases, Biomarkers, Interleukin-6, Matrix Metalloproteinase 7, Receptors, Tumor Necrosis Factor, Type I, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. https://app.cochat.ai/papers/10.1007/s00125-019-4859-4
The paper
Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019). Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. https://doi.org/10.1007/s00125-019-4859-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.